FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996604877> ?p ?o ?g. }

• W2996604877 endingPage "S904" @default.
• W2996604877 startingPage "S904" @default.
• W2996604877 abstract "Apremilast and biologics are commonly used as second-line treatments in Europe for moderate to severe plaque psoriasis, following conventional systemic disease-modifying antirheumatic drugs (i.e., csDMARDs). Previously, trial-based economic models demonstrated the cost-effectiveness of using apremilast earlier in treatment. Real-world costs associated with use of therapy also warrant exploration. Cost differences between csDMARD-experienced psoriasis patients newly initiating apremilast vs. a biologic were evaluated here. A retrospective analysis was conducted using WIG2 database, comprising ∼4 million German healthcare claims. Adults were selected if they: (1) newly initiated apremilast or a biologic during Feb2015-Jun2017 (assigned treatment group and index date), (2) were continuously enrolled for 12 months pre- and post-index, (3) had ≥1 csDMARD, ≥1 psoriasis diagnosis, and no cancer diagnosis pre-index, and (4) had no other psoriasis treatments within 30 days post-index. A 12-month intention-to-treat analysis was utilized to account for between-group treatment changes and to assess the overall impact of treatment on cost. Descriptive statistics and a linear regression model adjusting for demographics and Charlson Comorbidity Index (CCI) were used. Sensitivity analyses of anti-TNFs and secukinumab (IL-17A) subgroups were conducted. Costs were standardized to 2017€. Statistical significance was considered P≤0.05. A total of 420 patients were identified (i.e., napremilast=124, nbiologics=296, nanti-TNFs=142, nsecukinumab=97). Users of apremilast were significantly older (mean: 50 vs. 45 years) with higher CCI (mean: 2.81 vs. 1.96) vs. biologics. The unadjusted mean total cost per patient was significantly lower among users of apremilast (17,417€) vs. biologics (29,959€), anti-TNFs (30,372€), and secukinumab (29,486€). Differences were primarily driven by pharmacy costs (e.g., apremilast=14,118€; biologics=26,934€). The adjusted difference in mean total cost per patient was also significantly lower with apremilast vs. biologics (12,934€), anti-TNFs (13,015€), and secukinumab (12,608€). Real-world data confirm significant cost-savings with apremilast vs. biologics (average∼12,000€/patient), when used after csDMARDs. Limitations of claims data apply." @default.
• W2996604877 created "2019-12-26" @default.
• W2996604877 creator A5004243138 @default.
• W2996604877 creator A5017155171 @default.
• W2996604877 creator A5024860874 @default.
• W2996604877 creator A5058213635 @default.
• W2996604877 creator A5070921171 @default.
• W2996604877 creator A5081050169 @default.
• W2996604877 creator A5088757544 @default.
• W2996604877 date "2019-11-01" @default.
• W2996604877 modified "2023-10-14" @default.
• W2996604877 title "PSY17 REAL-WORLD COST DIFFERENCE IN PATIENTS WITH PSORIASIS NEWLY INITIATING APREMILAST VS. BIOLOGIC TREATMENT AFTER CONVENTIONAL SYSTEMIC THERAPY: A RETROSPECTIVE ANALYSIS OF GERMAN SICKNESS FUND DATA" @default.
• W2996604877 doi "https://doi.org/10.1016/j.jval.2019.09.2645" @default.
• W2996604877 hasPublicationYear "2019" @default.
• W2996604877 type Work @default.
• W2996604877 sameAs 2996604877 @default.
• W2996604877 citedByCount "0" @default.
• W2996604877 crossrefType "journal-article" @default.
• W2996604877 hasAuthorship W2996604877A5004243138 @default.
• W2996604877 hasAuthorship W2996604877A5017155171 @default.
• W2996604877 hasAuthorship W2996604877A5024860874 @default.
• W2996604877 hasAuthorship W2996604877A5058213635 @default.
• W2996604877 hasAuthorship W2996604877A5070921171 @default.
• W2996604877 hasAuthorship W2996604877A5081050169 @default.
• W2996604877 hasAuthorship W2996604877A5088757544 @default.
• W2996604877 hasBestOaLocation W29966048771 @default.
• W2996604877 hasConcept C126322002 @default.
• W2996604877 hasConcept C16005928 @default.
• W2996604877 hasConcept C167135981 @default.
• W2996604877 hasConcept C2776260265 @default.
• W2996604877 hasConcept C2777011040 @default.
• W2996604877 hasConcept C2780564577 @default.
• W2996604877 hasConcept C2781427535 @default.
• W2996604877 hasConcept C3020604521 @default.
• W2996604877 hasConcept C71924100 @default.
• W2996604877 hasConceptScore W2996604877C126322002 @default.
• W2996604877 hasConceptScore W2996604877C16005928 @default.
• W2996604877 hasConceptScore W2996604877C167135981 @default.
• W2996604877 hasConceptScore W2996604877C2776260265 @default.
• W2996604877 hasConceptScore W2996604877C2777011040 @default.
• W2996604877 hasConceptScore W2996604877C2780564577 @default.
• W2996604877 hasConceptScore W2996604877C2781427535 @default.
• W2996604877 hasConceptScore W2996604877C3020604521 @default.
• W2996604877 hasConceptScore W2996604877C71924100 @default.
• W2996604877 hasLocation W29966048771 @default.
• W2996604877 hasOpenAccess W2996604877 @default.
• W2996604877 hasPrimaryLocation W29966048771 @default.
• W2996604877 hasRelatedWork W1778948240 @default.
• W2996604877 hasRelatedWork W2185164199 @default.
• W2996604877 hasRelatedWork W2400036265 @default.
• W2996604877 hasRelatedWork W2405131717 @default.
• W2996604877 hasRelatedWork W2898206912 @default.
• W2996604877 hasRelatedWork W2914904476 @default.
• W2996604877 hasRelatedWork W2993521953 @default.
• W2996604877 hasRelatedWork W3159096017 @default.
• W2996604877 hasRelatedWork W3165742909 @default.
• W2996604877 hasRelatedWork W3189615335 @default.
• W2996604877 hasVolume "22" @default.
• W2996604877 isParatext "false" @default.
• W2996604877 isRetracted "false" @default.
• W2996604877 magId "2996604877" @default.
• W2996604877 workType "article" @default.